A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

The goal of this clinical trial is to learn about the safety of drug CG009301. It also learns if drug CG009301 works to treat in Participants with relapsed or refractory adult haematological malignancies. The main question\[s\] it aims to answer are: 1. To determine the maximum tolerated dose (MTD) and/or objective best dose (OBD) of CG009301 for injection in subjects with relapsed or refractory adult haematological malignancies. 2. To establish subsequent dosing regimens for CG009301 for injection. 3. To characterise the safety profile and tolerability of CG009301 for injection. Participant

Trial Details

NCT ID

NCT07347171

Phase

PHASE1

Sponsor

Cullgen (Shanghai),Inc

Status

RECRUITING

Cancer Type

Leukemia

Interventions

CG009301 for Injection

Locations (sample)

Nanchang, China|28.68396,115.85306
Tianjin, China|39.14222,117.17667
Wuhan, China|30.58333,114.26667

Key Eligibility Criteria

Age ≥18 years and \<75 years at the time of signing the informed consent form; no gender restrictions;
Patients with relapsed/refractory haematological malignancies who have received a definitive diagnosis by pathology and/or cytology, confirmed hist…
ECOG performance status score of 0-1;
Investigator-assessed expected survival ≥3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →